TY - JOUR
T1 - Ezetimibe decreased nonalcoholic fatty liver disease activity score but not hepatic steatosis
AU - Lee, Hyo Young
AU - Jun, Dae Won
AU - Kim, Hyun Jung
AU - Oh, Hyunwoo
AU - Saeed, Waqar Khalid
AU - Ahn, Hyeongsik
AU - Cheung, Ramsey C.
AU - Nguyen, Mindie H.
N1 - Funding Information:
This work was supported by a research fund from Ha-nyang University (HY-2014-C).
Funding Information:
This work was supported by a research fund from Hanyang University (HY-2014-C).
Publisher Copyright:
© 2019 The Korean Association of Internal Medicine.
Copyright:
Copyright 2019 Elsevier B.V., All rights reserved.
PY - 2019/3
Y1 - 2019/3
N2 - Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
AB - Background/Aims: A number of clinical trials reported varying effects of cholesterol lowering agents in nonalcoholic fatty liver disease (NAFLD) patients. We, therefore, assessed the changes in hepatic steatosis and NAFLD activity score (NAS) after treatment with cholesterol lowering agents in NAFLD patients by meta-analysis. Methods: The Cochrane Library, the MEDLINE, and the Embase databases were searched until May 2015, without any language restrictions, for randomized controlled trials (RCTs) and nonrandomized studies (NRSs). Additional references were obtained from review of bibliography of relevant articles. The quality of evidence was assessed using the grading of recommendations assessment, development and evaluation guidelines. Results: Three RCTs (n = 98) and two NRSs (n = 101) met our study inclusion criteria (adult, NAFLD, liver biopsy). Liver biopsy was performed in all five studies, but only the three studies reported NAS. Ezetimibe significantly decreased NAS (standardized mean difference [SMD], –0.30; 95% confidence interval [CI], –0.57 to –0.03) but not hepatic steatosis in RCT (SMD, –0.1; 95% CI, –0.53 to 0.32), while the effect was significant for both NAS and intrahepatic content in NRSs (SMD, –3.0; 95% CI, –6.9 to 0.91). Conclusions: Ezetimibe decreased NAS without improving hepatic steatosis.
KW - Ezetimibe
KW - Hydroxymethylglu-taryl-CoA reductase inhibitors
KW - Meta-analysis
KW - Non-alcoholic fatty liver disease
UR - http://www.scopus.com/inward/record.url?scp=85062613880&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85062613880&partnerID=8YFLogxK
U2 - 10.3904/kjim.2017.194
DO - 10.3904/kjim.2017.194
M3 - Article
C2 - 29551054
AN - SCOPUS:85062613880
VL - 34
SP - 296
EP - 304
JO - Korean Journal of Internal Medicine
JF - Korean Journal of Internal Medicine
SN - 0494-4712
IS - 2
ER -